EMERYVILLE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI) today announced that company researchers will be presenting at
the National Cancer Institute's Office of Cancer Complementary and Alternative
Medicine's (OCCAM) monthly lecture series. The title of the presentation is
"Selective Cytotoxic Activity of BZL 101 Towards Cancer Cells and Anti-Tumor
Effects in Patients with Advanced Breast Cancer," and will be presented by Dr.
Emma Shtivelman, Bionovo's Director of Cancer Research, and Dr. Mary
Tagliaferri, Bionovo's President and Chief Medical Officer.
Dr. Emma Shtivelman earned her Ph.D. in molecular biology from the
Weizmann Institute of Science, Israel. She was a postdoctoral associate at the
G.W. Hooper Research Foundation University of California, San Francisco. She
is the recipient of several awards including J. F. Kennedy Prize of Excellence
and the Israeli Parliament Award for Excellence in Studies. Dr. Shtivelman has
patents resulting from her work.
Dr. Mary Tagliaferri, a graduate from Cornell University, received her
medical degree from the University of California, San Francisco. She also
holds a master's degree in Traditional Chinese Medicine from the American
College of Traditional Chinese Medicine.
Dr. Tagliaferri has over 13 years experience in translational research
with the University of California, San Francisco and Bionovo, Inc. Dr.
Tagliaferri has spearheaded multiple scientific R & D projects to develop
pharmaceutical agents for indications in women's health and cancer. As one of
the co-founders of Bionovo Inc, she has extensive experience with FDA
regulatory affairs, and she has successfully filed a number of Investigational
New Drug Licenses (INDs). She has been involved in all aspects of drug
development, from preclinical testing to developing FDA approved protocols for
clinical trials. As the chief medical officer of Bionovo, she currently
manages and directs the daily activities of all clinical research projects
being conducted at prestigious medical centers throughout the United States
The lecture is scheduled to take place on Wednesday, February 4, 2009 from
3:00-4:00 PM EST at Executive Plaza North, 6130 Executive Blvd, Conference
Room H, Bethesda, MD 20892. The lecture is open to the public and a webcast
will become available a few weeks after the date of the lecture at:
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and cancer,
markets with significant unmet needs and billions in potential annual revenue.
The Company applies its expertise in the biology of menopause and cancer to
design new drugs derived from botanical sources which have novel mechanisms of
action. Based on the results of early and mid-stage clinical trials, Bionovo
believes they have discovered new classes of drug candidates within their rich
pipeline with the potential to be leaders in their markets. Bionovo's clinical
pipeline of drug candidates includes Menerba (MF101) for the treatment of
menopausal hot flashes and BZL101 for the treatment of advanced breast cancer.
Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ
Capital Market under the symbol, "BNVI". For more information about Bionovo
and its programs, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the
business of Bionovo, Inc. that can be identified by the use of forward-looking
terminology such as "believes," "expects," or similar expressions. Such
forward-looking statements involve known and unknown risks and uncertainties,
including uncertainties relating to product development, efficacy and safety,
regulatory actions or delays, the ability to obtain or maintain patent or
other proprietary intellectual property protection, market acceptance,
physician acceptance, third party reimbursement, future capital requirements,
competition in general and other factors that may cause actual results to be
materially different from those described herein as anticipated, believed,
estimated or expected. Certain of these risks and uncertainties are or will be
described in greater detail in our filings with the Securities and Exchange
Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under
no obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information, future
events or otherwise.
SOURCE Bionovo, Inc.
/CONTACT: Claire Fong, or Tom Chesterman, +1-510-601-2000,
email@example.com, both of Bionovo, Inc./
/Web Site: http://www.bionovo.com /
CO: Bionovo, Inc.; National Cancer Institute's Office of Cancer Complementary
and Alternative Medicine; OCCAM
IN: HEA MTC PHA
-- SF66788 --
8388 02/04/2009 13:04 EST http://www.prnewswire.com